Unlocking The Next Wave Of Cancer Vaccines: Advancing mRNA-LNP Delivery And Small-Scale Manufacturing, APAC Session

Personalized cancer vaccines (PCVs) are transforming immuno-oncology, but clinical translation remains hindered by challenges such as inefficient delivery, limited access to advanced lipid nanoparticle (LNP) formulations, and a lack of scalable manufacturing solutions for early-stage production.

This webinar highlights how optimized ionizable LNPs improve the delivery, translation, and antigen presentation of multi-epitope mRNA vaccines while maintaining safety, supported by preclinical data showing favorable tolerability and extended survival in tumor-bearing mice. It also explores how combining advanced LNP design with flexible, small-scale manufacturing technologies can streamline the path from development to clinical evaluation, helping teams build robust, scalable workflows and bring PCV candidates to the clinic more efficiently.